BiotechSign displays FDA Advisory Committee meetings only when the date is backed by public FDA, company, or SEC source material. Meetings are hidden until verified.
An FDA Advisory Committee is a panel of independent experts convened to vote on whether a drug's benefits outweigh its risks. While not binding, the FDA follows committee recommendations ~75% of the time.
AdCom meetings can matter because they surface public FDA concerns before a decision deadline. Verify the meeting source and review materials before relying on the date.
Not all drugs go through AdCom. The FDA uses committees for novel mechanisms, controversial safety profiles, or first-in-class drugs. The PDUFA date is the FDA's deadline to make the final decision.
A Complete Response Letter (CRL) is FDA's way of saying "not yet." Risk factors: manufacturing issues, clinical trial design questions, safety signals, or committee concerns not addressed.
Not financial advice. AdCom dates sourced from FDA.gov, company filings, and public disclosures. Dates may change without notice. Guerilla Finance Inc.